Lineage Cell Therapeutics
LCTX
LCTX
116 hedge funds and large institutions have $138M invested in Lineage Cell Therapeutics in 2024 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 29 increasing their positions, 32 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more ownership
Funds ownership: →
more funds holding
Funds holding: →
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 32
Holders
116
Holding in Top 10
3
Calls
$247K
Puts
–
Top Buyers
| 1 | +$9.96M | |
| 2 | +$9.25M | |
| 3 | +$2.02M | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.91M |
| 5 |
RA
Raffles Associates
New York
|
+$1.6M |
Top Sellers
| 1 | -$735K | |
| 2 | -$542K | |
| 3 | -$473K | |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$223K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$148K |